Handelsavisen
prelaunch
Companies Healthcare 4594.T
45
4594.T Tokyo Stock Exchange Biotechnology & Medical Research

4594.T

¥46,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
6,4B JPY
P/E
EV / Rev
Div yield
0,00 %
Op margin
-101 251,5 %
ROE
-124,4 %
Net margin
-101 601,9 %
Debt / equity
0,03
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-124,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4594.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4594.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with cash and equivalents amounting to ¥810.47 million, which is significantly higher than its total liabilities of ¥195.63 million, resulting in a current ratio of 8.14. The price-to-book ratio of 7.66 indicates that the market is valuing the company's equity at a premium relative to its book value. However, the company is currently unprofitable, with a net loss of ¥1.15 billion and an operating loss of ¥1.15 billion, which is reflected in a negative return on equity of -1.24 and a negative return on assets of -1.03.

    The company's profitability metrics are below the industry median for return on equity and return on assets, indicating underperformance in generating returns from its equity and asset base. The gross profit margin is high at ¥1.10 billion, but this is not translating into operating or net profits, suggesting significant operating expenses or cost overruns. The company's debt-to-equity ratio of 0.03 is low, indicating minimal leverage and a conservative capital structure.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which could expose it to regional economic or regulatory risks. The company's operating cash flow is negative at ¥1.25 billion, which is a concern for sustaining operations without external financing. The capital expenditure of ¥1.37 million is relatively low, suggesting limited investment in growth or expansion.

    The company's revenue of ¥1.13 billion is expected to remain flat in the current fiscal year, with no significant growth anticipated in the next fiscal year. The company's negative net income and operating income indicate a lack of profitability, which could affect its ability to grow organically or through acquisitions. The company's liquidity position is strong, but its negative cash flow from operations suggests a reliance on existing cash reserves to fund operations.

    The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and high cash reserves reduce the likelihood of near-term dilution or liquidity pressures. However, the company's negative net income and operating income could lead to future financing needs, potentially increasing dilution risk.

    The company has not disclosed any recent significant events, such as major filings or transcripts, that would indicate a change in its business strategy or financial position. The absence of recent events suggests a stable but unprofitable business model.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 8.14 and cash and equivalents of ¥810.47 million.
    • The company is unprofitable, with a net loss of ¥1.15 billion and an operating loss of ¥1.15 billion.
    • The company's debt-to-equity ratio is low at 0.03, indicating a conservative capital structure.
    • The company's return on equity and return on assets are negative, indicating poor profitability.
    • The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
    • The company's operating cash flow is negative, suggesting a reliance on existing cash reserves to fund operations.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥46,00
    Market cap
    ¥7.08B
    Enterprise value
    ¥6.30B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    7.7x
    P / Tangible book
    7.7x
    Tangible book
    ¥925.0M
    Net cash
    ¥785.5M
    Current ratio
    8.1
    Debt / equity
    0.0
    ROA
    -1.0%
    ROE
    -1.2%
    Cash conversion
    109.0%
    CapEx / revenue
    -1.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-101 251,5 %Bottom quartile
    Net Margin-101 601,9 %Bottom quartile
    ROE-124,4 %Bottom quartile
    Capex / Rev-120,9 %Bottom quartile
    D/E0,03Below median
    Cash Conv1,09Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 4594.T Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4594.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage